Important breakthroughs in medical treatments have improved outcomes for patients
suffering from several types of cancer. However, many oncological treatments approved by …

Importance Negative symptoms have a detrimental impact on functional outcomes and
quality of life in people with schizophrenia, and few therapeutic options are considered …

Background Many studies have recently been conducted to assess the antidepressant
efficacy of glutamate modification in mood disorders. This is an update of a review first …

Alzheimer's dementia (AD) is a major contributor to global disability, and effective therapies
to modify disease progression are currently lacking. The neuro-inflammatory theory is a …

Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy? |
The BMJ Skip to main content Intended for healthcare professionals Access provided by Google …

Background There is debate about the generalisability of results from randomised clinical
trials (RCTs) to real-world settings. Studying outcomes of treatments for schizophrenia can …

Policy Points Regulatory agencies may have limited evidence on the clinical benefits and
harms of new drugs when deciding whether new therapeutic agents are allowed to enter the …

Background and aims Nicotine is a highly addictive substance in tobacco products that
dysregulates several neurotransmitters in the brain and impairs executive function. Non …

Background Health systems experience difficult trade-offs when paying for new drugs. In
England, funding recommendations by the National Institute for Health and Care Excellence …

Objectives With complex health technologies entering the market, methods for health
technology assessment (HTA) may require changes. This study aimed to identify challenges …